<DOC>
	<DOCNO>NCT00686712</DOCNO>
	<brief_summary>To compare efficacy safety once-nightly insulin glargine versus single morning injection glargine once-nightly NPH insulin ethnic minority type 2 diabetic patient inadequately control combination oral agent .</brief_summary>
	<brief_title>Insulin Glargine Bedtime AM Versus NPH</brief_title>
	<detailed_description>Insulin glargine long action compare NPH insulin , whether result improve control use once-nightly morning basal insulin injection type 2 diabetic patient inadequately control combination oral agent controversial . Inner city ethnic minority patient diabetes particularly challenging population diabetic patient treat . This study investigate whether insulin glargine may effective safer first-line basal insulin NPH population .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Male female , age 1875 Type 2 diabetes diagnose least 1 year Treatment stable dos oral agent ( alone combination ) least 2 month Inadequate glycemic control ( hemoglobin A1c â‰¥ 7.5 % ) maximumtolerated dos sulfonylurea , metformin thiazolidinedione No past history chronic insulin use ( treatment gestational diabetes hospitalization less 1 week duration ) Hemoglobin A1c 7.5 % 12 % Body mass index ( BMI ) 20 40 kg/m2 Current previous chronic use insulin ( treatment gestational diabetes ) History confirm ( clinical suspicion ) type 1 diabetes Female subject childbearing potential sexually active use reliable form contraception Current pregnancy lactation . Subjects insulin therapy contraindicate , opinion investigator , therapy insulin indicate Subjects advance proliferative diabetic retinopathy Subjects work night shift unable stay consistent daily meal schedule History clinically significant renal , hepatic , cardiovascular , neurological , endocrinological major systemic disease , opinion investigator , may make implementation protocol interpretation data difficult . Subjects likely require initiate therapy drug may interfere glucose metabolism course study Subjects another investigational study receive another investigational medication within 30 day study entry Subjects unable unwilling comply component study protocol , include contact investigator specify time attend scheduled followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Glargine</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Basal insulin</keyword>
</DOC>